



Docket No.: 511582003500
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Mary FARIS, et al.

Application No.: 09/809,638

Filed: March 14, 2001

For: 125P5C8: A TISSUE SPECIFIC PROTEIN
HIGHLY EXPRESSED IN VARIOUS
CANCERS

Art Unit: 1643

Examiner: A. Harris

DECLARATION BY INVENTORS

UNDER 37 C.F.R. § 1.131

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

We, the undersigned, declare as follows:

1. We are co-inventors of claims 1, 14 and 23, currently pending in the above-referenced application. The claims relate to an isolated 125P5C8 protein comprising the sequence of SEQ ID NO: 2 or a polynucleotide sequence encoding the codons for SEQ ID NO: 2, which is exemplified by the nucleotide sequence of SEQ ID NO:1.

2. The Office rejected claims 1, 14 and 23 as allegedly being anticipated by WO 200270539 A2, which was filed March 5, 2002. This PCT application claims priority to U.S. Application No. 09/799,451, which was filed March 5, 2001, and is now U.S. Patent No. 6,783,989.

A copy of WO 200270539 was submitted in an Information Disclosure Statement provided in this application mailed on April 5, 2001. This document discloses sequence 1397 which is identical to SEQ ID NO: 2 of the present application.

3. We reduced the claimed invention to practice in the United States prior to the date U.S. Patent No. 6,783,989 was filed (March 5, 2001).

4. This reduction to practice is evidenced by a true and accurate copy of an email message sent to various members of the scientific staff by inventor Steve C. Mitchell on January 3, 2001. The email provides the nucleic acid and amino acid sequences of the material encompassed by the claims in the above-referenced patent application. A copy of this email is provided as Exhibit A.

5. The nucleotide sequence disclosed in Exhibit A consists of 2,103 nucleotides and 699 amino acids.

6. Exhibit B shows a comparison of the nucleotide sequence of SEQ ID NO:1 and the nucleotide sequence disclosed in Exhibit A. Every single nucleotide disclosed in SEQ ID NO:1 is present in the nucleotide sequence disclosed in Exhibit A. Accordingly, the email of Exhibit A clearly demonstrates the that nucleotide sequence of SEQ ID NO:1 was in our possession prior to the earliest priority date to which WO 200270539 (the cited art) is entitled to claim.

7. Exhibit C shows a comparison of the amino acid sequence of SEQ ID NO:2 and the amino acid sequence disclosed in Exhibit A. Every single amino acid residue disclosed in SEQ ID NO: 2 is present in the amino acid sequence disclosed in Exhibit A. Accordingly, the email of Exhibit A clearly demonstrates the that amino acid sequence of SEQ ID NO:2 was in our possession prior to the earliest priority date to which WO 200270539 (the cited art) is entitled to claim.

8. In view of the email provided as Exhibit A and the analysis of the sequences disclosed therein and shown in Exhibits B and C, we declare that the invention of the pending claims was reduced to practice in the United States prior to March 5, 2001, the earliest priority date available to the cited document.

We declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date

Executed at

01/26/2006 Santa Monica, CA Aya Jakobovits
(City/State) Aya JAKOBOVITS

(City/State) Daniel E.H. AFAR

(City/State) Steve Chappell MITCHELL

1/27/06 Santa Monica, CA Pia M. Challita-Eid
(City/State) Pia M. CHALLITA-EID

1-27-06 Santa Monica CA Arthur B. Raitano
(City/State) Arthur B. RAITANO


(City/State) Mary FARIS

8. In view of the email provided as Exhibit A and the analysis of the sequences disclosed therein and shown in Exhibits B and C, we declare that the invention of the pending claims was reduced to practice in the United States prior to March 5, 2001, the earliest priority date available to the cited document.

We declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date

Executed at

<u>2/1/2006</u>	<u>(City/State)</u> <u>FREMONT, CA</u> <u>(City/State)</u>	<u>Aya JAKOBOVITS</u>  <u>Daniel E.H. AFAR</u>
<u> </u>	<u>(City/State)</u>	<u>Steve Chappell MITCHELL</u>
<u> </u>	<u>(City/State)</u>	<u>Pia M. CHALLITA-EID</u>
<u> </u>	<u>(City/State)</u>	<u>Arthur B. RAITANO</u>
<u> </u>	<u>(City/State)</u>	<u>Mary FARIS</u>

Popp, Shane

From: Mitchell, Steve
Sent: Wednesday, January 03, 2001 1:43 PM
To: Scientists
Subject: 125P5C8 reagents.

Colleagues,

The Company reagent for 125P5C8 (124P1B7/139P3A1) is posted. It is a PCR based pCR2.1/TA clone(prostate) with three point differences from the Japanese (colon) reported hypothetical sequence.
Two point are conserved for translation whereas the third point difference gives an amino acid change near the 3 prime end. This is verified with genomic sequencing.

>125P5C8(124P1B7/139P3A1) pCR2.1 subclone

```
CGATGACCTCGCTGTGGAGAGAAATCCTCTTGGAGTCGCTGCTGGGATGTGTTTCTTGGTCTCTCTACCATGACCTGGGACCGATG
ATCTATTACTTTCTTTGCAAACTAGAACTCACTGGGCTTGAAGGTTTGTAGTATAGCATTTCTTTCTCCAATATTCCTAACAATTACT
CCTTCTCGAAATGGTTAACAAGAGTGGGATGCTAACCTGCTGAGGATAATCACTATTGGCAGCATAGCCTCCTTCCAGGCTCCA
AATGCCAAACTTCGACTGATGTTCTTGGCGCTTGGGGTGTCTTCTCACTGATAGTGCAAGCTGTGACTTGGTGGTCCGGGAAGTCAT
TTGCAAGGTACCTCAGAAATTTGGGGATTCATTTAGGACAGATTGTTCTTGTGTTCTACGCATATGGTATACTTCACTAAACCCAAAT
CTGGAGTTATCAGATGTCCAACAAAGTGATACTGACATTAAGTGCCATAGCCACACTTGATCGTATTGGCACAGATGGTGACTGCAG
TAAACCTGAAGAAAAGAGACTGGTGAGGTAGCCACGGGGATGGCCTCTAGACCCAACTGGCTGCTGGCAGGGGCTGCTTTTGGT
AGCCTTGTGTTCTCACTGGGTTTGGAGAAGTCTCTTGTTCAGATGGGCAGTGAGTGGGCATCCACATCCAGGGGCC
AGATCCTAACCCATTGGAGGTGCAGTACTGCTGTGCTTGGCAAGTGGATTGATGCTTCCATCTTGTGTTGGTTTCGTGGTACTGG
TTTGATCTGGTGGTTACAGGAACAGCTTCAGCTGCGGGGCTCCTTACCTGCACACATGGGCAAGCTGCTGTGTCTGGCTGTGTCT
TCGCCATCTTTACTGCATCCATGTGGCCCCAAACACTTGGACACCTTATTAACCTCAGGGACAAACCTGGGAAAACCATGACCATTG
CCATGATATTTATCTCTAGAAATATTTTCTGTGCTGGTGGTGACAGCTTTTAAAGTTTGTCCAGGAGGTGTCTACGCTAGAGAAAG
ATCAGATGTGCTTTTGGGACAAATGATGTTAATTATCGGGCTGAATATGCTATTTGGTCTAAGAAAAACCTTGACTTGGTTCTTCAA
ACAAAAAACAGTTCTAAAGTGCTTTTCAAGAAAGAGTGAAAAATACATGAACTTTTCTGTGGCTGCTTGTGGTGTGGGATTGTGG
GATTAGGACTACGGCATAAAGCCTATGAGAGAAAACCTGGGCAAGTGCCACCAACCAAGAGGTCTCTGCTGCCATCTGGCCTTTC
AGGTTTGGATATGACAATGAAGGGTGGTCTAGTCTAGAAAGATCAGCTCACCTGCTCAATGAAACAGGTGCAGATTTCAATAAAT
TTGGAGAGTGATGCTTCTAAGCCCTATATGGGGAACATGACTTAACCATGTGGCTAGGGGAAAAGTTGGGTTTCTATACAGACTTT
GGTCCAAGCACAAAGGTATCACACTTGGGGGATTATGGCTTTGTCAAGATACCAATTGTGAAATCTGAGCATCACCTTCTTCCGTCA
CCAGAGGGGCGAGATCGCACAGCCATCACATTGACCGTTAACATTTGGGGCAAGCTGGTGGATTTTGTGCTGACACACTTTGGGAA
CCACGAAGATGACCTCGACAGGAACTGCAGGCTATTGCTGTTTCAAACTACTGAAAAGTAGCTCTAATCAAGTGATATTTCTGGG
ATATATCACTTCAAGCACTGGCTCCAGAGATTATCTACAGCTCACTGAACATGGCAATGTGAAGGATATCGACAGCACTGATCATGA
CAGATGGTGTGAATACATTATGTATCGAGGGCTGATCAGGTGGGTTATGCAAGAATCTCCCATGCTGAAGTGAAGTGAAGTGAAGT
TCAGATGGCAAAATTTAGGATCCCTGATGACCCCACTAATTATAGAGACAACCAGAAAGTGGTCATAGACCACAGAGAAGTTTCTGA
GAAAATTCAATTTAATCCAGATTGGATCCTACAAAGAAGGACACAATTATGAAAACAACCATCATTTTCATATGAATACTCCCAAT
ACTTTTATGAAAC
```

>125P5C8(124P1B7/139P3A1) pCR2.1 subclone

```
MTSLWREILLESLLGCYSWSLYHDLGPMIYYFPLQLELTGLEGFSIAFLSPFLTTPFWKLWNKKWMLTLRLITIGSIASFQAPNAKLRLM
/LALGVSSSLIVQAVTWWSGSHLQRYLRWGFILGQIVLVLRWYTSLNPIWVSYQMSNKKVILTLAJATLDRIGTDGDCSKPEEKKTGEVA
/GMASRPNWLLAGAAFGSLVFLTHWVFGEVSLVSRWAVSGHPHPGDPNPFGGAVLLCLASGLMLPSCSLWFRGTGLUWVVTGTASAA
/LLYLHTWAAVSGCVFAIFTASMWPTLGHUNSGTNPGKMTMTIAMIFYLLEIFFCAWCTAFKFVPGGVYARERSDVLLGTMMLIIGLNML
/GPKKNLDLLQTKNSKVLFRKSEKYMKFLWLLVGVGLLGLGLRHKAYERKLGKVPATKEVSAIWPFRFGYDNEGWSLSERSAHL
/IETGADFITILESASKPYMGNDLTMWLGEKLGFTDFGPSTRYHTWGIMALSRYPIVKSEHLLPSPEGEIAPATLTWNISGKLVDFFV
/HFGNHEDDLDRKLQAIKAVSKLLKSSSNQVFLGYITSAPGSRDYQLTEHGNVKDIDSTDHWRWCEYIMYRGLRLGYARISHAELSDSEI
/IMAKFRIPDDPTNYRONQKVVIDHREVSEKIHFNPRFGSYKEGHYENNIHIFHMNTPKYFL
```

Steve Chappell Mitchell
Associate Scientist
uGenesys
101 Colorado Avenue
Santa Monica, CA 90404
t (310)820-8029 x261
f (310)820-8489
mail smitchell@urogenesys.com
www.urogenesys.com

Exhibit B**A Comparison of SEQ ID NO.:1 and the Nucleotide Sequence of the Email**

atgacctcgc	tgtggagaga	aatcctcttg	gagtcgctgc	tgggatgtgt	ttcttggtct	SID#1
cg atgacctcgc	tgtggagaga	aatcctcttg	gagtcgctgc	tgggatgtgt	ttcttggtct	Email

ctctaccatg	acctgggacc	gatgatctat	tactttcctt	tgcaaact	agaactcact	SID#1
ctctaccatg	acctgggacc	gatgatctat	tactttcctt	tgcaaact	agaactcact	Email

gggcttgaag	gttttagtat	agcatttctt	tctccaatat	tcctaacaat	tactcctttc	SID#1
gggcttgaag	gttttagtat	agcatttctt	tctccaatat	tcctaacaat	tactcctttc	Email

tggaaattgg	ttaacaagaa	gtggatgcta	accctgctga	ggataatcac	tattggcagc	SID#1
tggaaattgg	ttaacaagaa	gtggatgcta	accctgctga	ggataatcac	tattggcagc	Email

atagcctcct	tccaggctcc	aaatgccaaa	cttcgactga	tggttcttgc	gcttgggggtg	SID#1
atagcctcct	tccaggctcc	aaatgccaaa	cttcgactga	tggttcttgc	gcttgggggtg	Email

tcttcctcac	tgatagtgc	agctgtgact	tggtggtcgg	gaagtcattt	gcaaaggtac	SID#1
tcttcctcac	tgatagtgc	agctgtgact	tggtggtcgg	gaagtcattt	gcaaaggtac	Email

ctcagaattt	ggggattcat	tttaggacag	attgttcttg	ttgttctacg	catatgggtat	SID#1
ctcagaattt	ggggattcat	tttaggacag	attgttcttg	ttgttctacg	catatgggtat	Email

acttcactaa	acccaatctg	gagttatcag	atgtccaaca	aagtgatact	gacattaagt	SID#1
acttcactaa	acccaatctg	gagttatcag	atgtccaaca	aagtgatact	gacattaagt	Email

gccatagcca	cacttgatcg	tattggcaca	gatggtgact	gcagtaaacc	tgaagaaaag	SID#1
gccatagcca	cacttgatcg	tattggcaca	gatggtgact	gcagtaaacc	tgaagaaaag	Email

aagactgggtg	aggtagccac	ggggatggcc	tctagacca	actggctgct	ggcaggggct	SID#1
aagactgggtg	aggtagccac	ggggatggcc	tctagacca	actggctgct	ggcaggggct	Email

gcttttggtg	gccttggtg	cctcaccac	tgggtttttg	gagaagtctc	tcttggttcc	SID#1
gcttttggtg	gccttggtg	cctcaccac	tgggtttttg	gagaagtctc	tcttggttcc	Email

Exhibit B
A Comparison of SEQ ID NO.:1 and the Nucleotide Sequence of the Email

agatgggcag	tgagtgggca	tccacatcca	gggccagatc	ctaaccatt	tggaggtgca	SID#1
agatgggcag	tgagtgggca	tccacatcca	gggccagatc	ctaaccatt	tggaggtgca	Email

gtactgctgt	gcttggcaag	tggattgatg	cttccatctt	gtttgtggtt	tcgtggtact	SID#1
gtactgctgt	gcttggcaag	tggattgatg	cttccatctt	gtttgtggtt	tcgtggtact	Email

ggtttgatct	ggtgggttac	aggaacagct	tcagctgcgg	ggctccttta	cctgcacaca	SID#1
ggtttgatct	ggtgggttac	aggaacagct	tcagctgcgg	ggctccttta	cctgcacaca	Email

tgggcagctg	ctgtgtctgg	ctgtgtcttc	gccatcttta	ctgcatccat	gtggcccaa	SID#1
tgggcagctg	ctgtgtctgg	ctgtgtcttc	gccatcttta	ctgcatccat	gtggcccaa	Email

acacttgga	accttattaa	ctcagggaca	aaccctggga	aaaccatgac	cattgccatg	SID#1
acacttgga	accttattaa	ctcagggaca	aaccctggga	aaaccatgac	cattgccatg	Email

atatattatc	ttctagaaat	atatttctgt	gcctggtgca	cagcttttaa	gtttgtccca	SID#1
atatattatc	ttctagaaat	atatttctgt	gcctggtgca	cagcttttaa	gtttgtccca	Email

ggaggtgtct	acgctagaga	aagatcagat	gtgcttttgg	ggacaatgat	gttaattatc	SID#1
ggaggtgtct	acgctagaga	aagatcagat	gtgcttttgg	ggacaatgat	gttaattatc	Email

gggctgaata	tgctatttgg	tcctaagaaa	aaccttgact	tgcttcttca	aacaaaaaac	SID#1
gggctgaata	tgctatttgg	tcctaagaaa	aaccttgact	tgcttcttca	aacaaaaaac	Email

agttctaaag	tgcttttcag	aaagagtga	aaatacatga	aactttttct	gtggctgctt	SID#1
agttctaaag	tgcttttcag	aaagagtga	aaatacatga	aactttttct	gtggctgctt	Email

gttggtgtgg	gattgttggg	attaggacta	cggcataaag	cctatgagag	aaaactgggc	SID#1
gttggtgtgg	gattgttggg	attaggacta	cggcataaag	cctatgagag	aaaactgggc	

Exhibit B**A Comparison of SEQ ID NO.:1 and the Nucleotide Sequence of the Email**

aaagtggcac	caaccaaaga	ggctctctgct	gccatctggc	ctttcagggt	tggatatgac	SID#1
aaagtggcac	caaccaaaga	ggctctctgct	gccatctggc	ctttcagggt	tggatatgac	Email
aatgaagggt	ggctctagtct	agaaagatca	gctcacctgc	tcaatgaaac	aggtgcagat	SID#1
aatgaagggt	ggctctagtct	agaaagatca	gctcacctgc	tcaatgaaac	aggtgcagat	Email
ttcataacaa	ttttggagag	tgatgcttct	aagccctata	tggggaacaa	tgacttaacc	SID#1
ttcataacaa	ttttggagag	tgatgcttct	aagccctata	tggggaacaa	tgacttaacc	Email
atgtggctag	gggaaaagt	gggtttctat	acagactttg	gtccaagcac	aaggtatcac	SID#1
atgtggctag	gggaaaagt	gggtttctat	acagactttg	gtccaagcac	aaggtatcac	Email
acttggggga	ttatggcttt	gtcaagatac	ccaattgtga	aatctgagca	tcaccttctt	SID#1
acttggggga	ttatggcttt	gtcaagatac	ccaattgtga	aatctgagca	tcaccttctt	Email
ccgtcaccag	agggcgagat	cgcaccagcc	atcacattga	ccgttaacat	ttcgggcaag	SID#1
ccgtcaccag	agggcgagat	cgcaccagcc	atcacattga	ccgttaacat	ttcgggcaag	Email
ctgggtgatt	ttgtcgtgac	acactttggg	aaccacgaag	atgacctcga	caggaaactg	SID#1
ctgggtgatt	ttgtcgtgac	acactttggg	aaccacgaag	atgacctcga	caggaaactg	Email
caggctattg	ctgtttcaaa	actactgaaa	agtagctcta	atcaagtgat	atttctggga	SID#1
caggctattg	ctgtttcaaa	actactgaaa	agtagctcta	atcaagtgat	atttctggga	Email
tatatcactt	cagcacctgg	ctccagagat	tatctacagc	tcactgaaca	tggcaatgtg	SID#1
tatatcactt	cagcacctgg	ctccagagat	tatctacagc	tcactgaaca	tggcaatgtg	Email
aaggatatcg	acagcactga	tcatgacaga	tgggtgtaat	acattatgta	tcgagggctg	SID#1
aaggatatcg	acagcactga	tcatgacaga	tgggtgtaat	acattatgta	tcgagggctg	Email
atcaggttgg	gttatgcaag	aatctcccat	gctgaactga	gtgattcaga	aattcagatg	SID#1
atcaggttgg	gttatgcaag	aatctcccat	gctgaactga	gtgattcaga	aattcagatg	

Exhibit B**A Comparison of SEQ ID NO.:1 and the Nucleotide Sequence of the Email**

gcaaaattta	ggatccctga	tgacccact	aattatagag	acaaccagaa	agtggtcata	SID#1
gcaaaattta	ggatccctga	tgacccact	aattatagag	acaaccagaa	agtggtcata	Email

gaccacagag	aagtttctga	gaaaattcat	tttaatccca	gatttggatc	ctacaaagaa	SID#1
gaccacagag	aagtttctga	gaaaattcat	tttaatccca	gatttggatc	ctacaaagaa	Email

ggacacaatt	atgaaaacaa	ccatcatttt	catatgaata	ctcccaaata	ctttttatga	SID#1
ggacacaatt	atgaaaacaa	ccatcatttt	catatgaata	ctcccaaata	ctttttatga	Email

aac	SID#1
aac	Email

Exhibit C**A Comparison of SEQ ID NO.:2 and the Nucleotide Sequence of the Email**

Met Thr Ser Leu Trp Arg Glu Ile Leu Leu Glu Ser Leu Leu Gly (SID #2)
 | | | | | | | | | | | | | |
 Met Thr Ser Leu Trp Arg Glu Ile Leu Leu Glu Ser Leu Leu Gly (Email)

Cys Val Ser Trp Ser Leu Tyr His Asp Leu Gly Pro Met Ile Tyr Tyr (SID #2)
 | | | | | | | | | | | | | |
 Cys Val Ser Trp Ser Leu Tyr His Asp Leu Gly Pro Met Ile Tyr Tyr (Email)

Phe Pro Leu Gln Thr Leu Glu Leu Thr Gly Leu Glu Gly Phe Ser Ile (SID #2)
 | | | | | | | | | | | | | |
 Phe Pro Leu Gln Thr Leu Glu Leu Thr Gly Leu Glu Gly Phe Ser Ile (Email)

Ala Phe Leu Ser Pro Ile Phe Leu Thr Ile Thr Pro Phe Trp Lys Leu (SID #2)
 | | | | | | | | | | | | | |
 Ala Phe Leu Ser Pro Ile Phe Leu Thr Ile Thr Pro Phe Trp Lys Leu (Email)

Val Asn Lys Lys Trp Met Leu Thr Leu Leu Arg Ile Ile Thr Ile Gly (SID #2)
 | | | | | | | | | | | | | |
 Val Asn Lys Lys Trp Met Leu Thr Leu Leu Arg Ile Ile Thr Ile Gly (Email)

Ser Ile Ala Ser Phe Gln Ala Pro Asn Ala Lys Leu Arg Leu Met Val (SID #2)
 | | | | | | | | | | | | | |
 Ser Ile Ala Ser Phe Gln Ala Pro Asn Ala Lys Leu Arg Leu Met Val (Email)

Leu Ala Leu Gly Val Ser Ser Ser Leu Ile Val Gln Ala Val Thr Trp (SID #2)
 | | | | | | | | | | | | | |
 Leu Ala Leu Gly Val Ser Ser Ser Leu Ile Val Gln Ala Val Thr Trp (Email)

Trp Ser Gly Ser His Leu Gln Arg Tyr Leu Arg Ile Trp Gly Phe Ile (SID #2)
 | | | | | | | | | | | | | |
 Trp Ser Gly Ser His Leu Gln Arg Tyr Leu Arg Ile Trp Gly Phe Ile (Email)

Leu Gly Gln Ile Val Leu Val Val Leu Arg Ile Trp Tyr Thr Ser Leu (SID #2)
 | | | | | | | | | | | | | |
 Leu Gly Gln Ile Val Leu Val Val Leu Arg Ile Trp Tyr Thr Ser Leu (Email)

Asn Pro Ile Trp Ser Tyr Gln Met Ser Asn Lys Val Ile Leu Thr Leu (SID #2)
 | | | | | | | | | | | | | |
 Asn Pro Ile Trp Ser Tyr Gln Met Ser Asn Lys Val Ile Leu Thr Leu (Email)

Ser Ala Ile Ala Thr Leu Asp Arg Ile Gly Thr Asp Gly Asp Cys Ser (SID #2)
 | | | | | | | | | | | | | |
 Ser Ala Ile Ala Thr Leu Asp Arg Ile Gly Thr Asp Gly Asp Cys Ser (Email)

Exhibit C**A Comparison of SEQ ID NO.:2 and the Nucleotide Sequence of the Email**

Lys Pro Glu Glu Lys Lys Thr Gly Glu Val Ala Thr Gly Met Ala Ser (SID #2)
 | | | | | | | | | | | | | | |
 Lys Pro Glu Glu Lys Lys Thr Gly Glu Val Ala Thr Gly Met Ala Ser (Email)

Arg Pro Asn Trp Leu Leu Ala Gly Ala Ala Phe Gly Ser Leu Val Phe (SID #2)
 | | | | | | | | | | | | | | |
 Arg Pro Asn Trp Leu Leu Ala Gly Ala Ala Phe Gly Ser Leu Val Phe (Email)

Leu Thr His Trp Val Phe Gly Glu Val Ser Leu Val Ser Arg Trp Ala (SID #2)
 | | | | | | | | | | | | | | |
 Leu Thr His Trp Val Phe Gly Glu Val Ser Leu Val Ser Arg Trp Ala (Email)

Val Ser Gly His Pro His Pro Gly Pro Asp Pro Asn Pro Phe Gly Gly (SID #2)
 | | | | | | | | | | | | | | |
 Val Ser Gly His Pro His Pro Gly Pro Asp Pro Asn Pro Phe Gly Gly (Email)

Ala Val Leu Leu Cys Leu Ala Ser Gly Leu Met Leu Pro Ser Cys Leu (SID #2)
 | | | | | | | | | | | | | | |
 Ala Val Leu Leu Cys Leu Ala Ser Gly Leu Met Leu Pro Ser Cys Leu (Email)

Trp Phe Arg Gly Thr Gly Leu Ile Trp Trp Val Thr Gly Thr Ala Ser (SID #2)
 | | | | | | | | | | | | | | |
 Trp Phe Arg Gly Thr Gly Leu Ile Trp Trp Val Thr Gly Thr Ala Ser (Email)

Ala Ala Gly Leu Leu Tyr Leu His Thr Trp Ala Ala Ala Val Ser Gly (SID #2)
 | | | | | | | | | | | | | | |
 Ala Ala Gly Leu Leu Tyr Leu His Thr Trp Ala Ala Ala Val Ser Gly (Email)

Cys Val Phe Ala Ile Phe Thr Ala Ser Met Trp Pro Gln Thr Leu Gly (SID #2)
 | | | | | | | | | | | | | | |
 Cys Val Phe Ala Ile Phe Thr Ala Ser Met Trp Pro Gln Thr Leu Gly (Email)

His Leu Ile Asn Ser Gly Thr Asn Pro Gly Lys Thr Met Thr Ile Ala (SID #2)
 | | | | | | | | | | | | | | |
 His Leu Ile Asn Ser Gly Thr Asn Pro Gly Lys Thr Met Thr Ile Ala (Email)

Met Ile Phe Tyr Leu Leu Glu Ile Phe Phe Cys Ala Trp Cys Thr Ala (SID #2)
 | | | | | | | | | | | | | | |
 Met Ile Phe Tyr Leu Leu Glu Ile Phe Phe Cys Ala Trp Cys Thr Ala (Email)

Phe Lys Phe Val Pro Gly Gly Val Tyr Ala Arg Glu Arg Ser Asp Val (SID #2)
 | | | | | | | | | | | | | | |
 Phe Lys Phe Val Pro Gly Gly Val Tyr Ala Arg Glu Arg Ser Asp Val (Email)

Exhibit C**A Comparison of SEQ ID NO.:2 and the Nucleotide Sequence of the Email**

Leu Leu Gly Thr Met Met Leu Ile Ile Gly Leu Asn Met Leu Phe Gly (SID #2)
 | | | | | | | | | | | | | | | |
 Leu Leu Gly Thr Met Met Leu Ile Ile Gly Leu Asn Met Leu Phe Gly (Email)

Pro Lys Lys Asn Leu Asp Leu Leu Leu Gln Thr Lys Asn Ser Ser (SID #2)
 | | | | | | | | | | | | | | | |
 Pro Lys Lys Asn Leu Asp Leu Leu Leu Gln Thr Lys Asn Ser Ser (Email)

Lys Val Leu Phe Arg Lys Ser Glu Lys Tyr Met Lys Leu Phe Leu Trp (SID #2)
 | | | | | | | | | | | | | | | |
 Lys Val Leu Phe Arg Lys Ser Glu Lys Tyr Met Lys Leu Phe Leu Trp (Email)

Leu Leu Val Gly Val Gly Leu Leu Gly Leu Gly Leu Arg His Lys Ala (SID #2)
 | | | | | | | | | | | | | | | |
 Leu Leu Val Gly Val Gly Leu Leu Gly Leu Gly Leu Arg His Lys Ala (Email)

Tyr Glu Arg Lys Leu Gly Lys Val Ala Pro Thr Lys Glu Val Ser Ala Ala (SID #2)
 | | | | | | | | | | | | | | | |
 Tyr Glu Arg Lys Leu Gly Lys Val Ala Pro Thr Lys Glu Val Ser Ala Ala (Email)

Ile Trp Pro Phe Arg Phe Gly Tyr Asp Asn Glu Gly Trp Ser Ser (SID #2)
 | | | | | | | | | | | | | | | |
 Ile Trp Pro Phe Arg Phe Gly Tyr Asp Asn Glu Gly Trp Ser Ser (Email)

Leu Glu Arg Ser Ala His Leu Leu Asn Glu Thr Gly Ala Asp Phe Ile (SID #2)
 | | | | | | | | | | | | | | | |
 Leu Glu Arg Ser Ala His Leu Leu Asn Glu Thr Gly Ala Asp Phe Ile (Email)

Thr Ile Leu Glu Ser Asp Ala Ser Lys Pro Tyr Met Gly Asn Asn Asp (SID #2)
 | | | | | | | | | | | | | | | |
 Thr Ile Leu Glu Ser Asp Ala Ser Lys Pro Tyr Met Gly Asn Asn Asp (Email)

Leu Thr Met Trp Leu Gly Glu Lys Leu Gly Phe Tyr Thr Asp Phe Gly (SID #2)
 | | | | | | | | | | | | | | | |
 Leu Thr Met Trp Leu Gly Glu Lys Leu Gly Phe Tyr Thr Asp Phe Gly (Email)

Pro Ser Thr Arg Tyr His Thr Trp Gly Ile Met Ala Leu Ser Arg Tyr (SID #2)
 | | | | | | | | | | | | | | | |
 Pro Ser Thr Arg Tyr His Thr Trp Gly Ile Met Ala Leu Ser Arg Tyr (Email)

Pro Ile Val Lys Ser Glu His His Leu Leu Pro Ser Pro Glu Gly Glu (SID #2)
 | | | | | | | | | | | | | | | |
 Pro Ile Val Lys Ser Glu His His Leu Leu Pro Ser Pro Glu Gly Glu (Email)

Exhibit C**A Comparison of SEQ ID NO.:2 and the Nucleotide Sequence of the Email**

Ile	Ala	Pro	Ala	Ile	Thr	Leu	Thr	Val	Asn	Ile	Ser	Gly	Lys	Leu	Val	(SID #2)
Ile	Ala	Pro	Ala	Ile	Thr	Leu	Thr	Val	Asn	Ile	Ser	Gly	Lys	Leu	Val	(Email)

Asp	Phe	Val	Val	Thr	His	Phe	Gly	Asn	His	Glu	Asp	Asp	Leu	Asp	Arg	(SID #2)
Asp	Phe	Val	Val	Thr	His	Phe	Gly	Asn	His	Glu	Asp	Asp	Leu	Asp	Arg	(Email)

Lys	Leu	Gln	Ala	Ile	Ala	Val	Ser	Lys	Leu	Leu	Lys	Ser	Ser	Ser	Asn	(SID #2)
Lys	Leu	Gln	Ala	Ile	Ala	Val	Ser	Lys	Leu	Leu	Lys	Ser	Ser	Ser	Asn	(Email)

Gln	Val	Ile	Phe	Leu	Gly	Tyr	Ile	Thr	Ser	Ala	Pro	Gly	Ser	Arg	Asp	(SID #2)
Gln	Val	Ile	Phe	Leu	Gly	Tyr	Ile	Thr	Ser	Ala	Pro	Gly	Ser	Arg	Asp	

Tyr	Leu	Gln	Leu	Thr	Glu	His	Gly	Asn	Val	Lys	Asp	Ile	Asp	Ser	Thr	(SID #2)
Tyr	Leu	Gln	Leu	Thr	Glu	His	Gly	Asn	Val	Lys	Asp	Ile	Asp	Ser	Thr	(Email)

Asp	His	Asp	Arg	Trp	Cys	Glu	Tyr	Ile	Met	Tyr	Arg	Gly	Leu	Ile	Arg	(SID #2)
Asp	His	Asp	Arg	Trp	Cys	Glu	Tyr	Ile	Met	Tyr	Arg	Gly	Leu	Ile	Arg	(Email)

Leu	Gly	Tyr	Ala	Arg	Ile	Ser	His	Ala	Glu	Leu	Ser	Asp	Ser	Glu	Ile	(SID #2)
Leu	Gly	Tyr	Ala	Arg	Ile	Ser	His	Ala	Glu	Leu	Ser	Asp	Ser	Glu	Ile	(Email)

Gln	Met	Ala	Lys	Phe	Arg	Ile	Pro	Asp	Asp	Pro	Thr	Asn	Tyr	Arg	Asp	(SID #2)
Gln	Met	Ala	Lys	Phe	Arg	Ile	Pro	Asp	Asp	Pro	Thr	Asn	Tyr	Arg	Asp	(Email)

Asn	Gln	Lys	Val	Val	Ile	Asp	His	Arg	Glu	Val	Ser	Glu	Lys	Ile	His	(SID #2)
Asn	Gln	Lys	Val	Val	Ile	Asp	His	Arg	Glu	Val	Ser	Glu	Lys	Ile	His	(SID #2)

Phe	Asn	Pro	Arg	Phe	Gly	Ser	Tyr	Lys	Glu	Gly	His	Asn	Tyr	Glu	Asn	(SID #2)
Phe	Asn	Pro	Arg	Phe	Gly	Ser	Tyr	Lys	Glu	Gly	His	Asn	Tyr	Glu	Asn	(Email)

Asn	His	His	Phe	His	Met	Asn	Thr	Pro	Lys	Tyr	Phe	Leu	(SID #2)
Asn	His	His	Phe	His	Met	Asn	Thr	Pro	Lys	Tyr	Phe	Leu	(Email)